Education
About Us
Working with TipRanks
Follow Us
Modus Therapeutics Holding AB (SE:MODTX)
:MODTX
MODTX Stock Chart & Stats
kr0.36
-kr0.02(-1.23%)
At close: 4:00 PM EST
kr0.36
-kr0.02(-1.23%)
Day’s Range― - ―
52-Week Rangekr0.32 - kr5.00
Previous CloseN/A
Volume636.00
Average Volume (3M)841.43K
Market Cap
kr44.15M
Enterprise Valuekr46.23M
Total Cash (Recent Filing)kr5.32M
Total Debt (Recent Filing)kr5.00M
Price to Earnings (P/E)―
Beta2.29
Next Earnings
Feb 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding121,628,494
10 Day Avg. Volume409,277
30 Day Avg. Volume841,432
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)30.44
Price to Sales (P/S)0.00
P/FCF Ratio-4.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
MODTX FAQ
What was Modus Therapeutics Holding AB’s price range in the past 12 months?
Modus Therapeutics Holding AB lowest stock price was kr0.32 and its highest was kr5.00 in the past 12 months.
What is Modus Therapeutics Holding AB’s market cap?
Modus Therapeutics Holding AB’s market cap is kr44.15M.
When is Modus Therapeutics Holding AB’s upcoming earnings report date?
Modus Therapeutics Holding AB’s upcoming earnings report date is Feb 25, 2026 which is in 71 days.
How were Modus Therapeutics Holding AB’s earnings last quarter?
Modus Therapeutics Holding AB released its earnings results on Nov 26, 2025. The company reported -kr0.077 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.077.
Is Modus Therapeutics Holding AB overvalued?
According to Wall Street analysts Modus Therapeutics Holding AB’s price is currently Overvalued.
Does Modus Therapeutics Holding AB pay dividends?
Modus Therapeutics Holding AB does not currently pay dividends.
What is Modus Therapeutics Holding AB’s EPS estimate?
Modus Therapeutics Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Modus Therapeutics Holding AB have?
Modus Therapeutics Holding AB has 121,628,494 shares outstanding.
What happened to Modus Therapeutics Holding AB’s price movement after its last earnings report?
Modus Therapeutics Holding AB reported an EPS of -kr0.077 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.368%.
Which hedge fund is a major shareholder of Modus Therapeutics Holding AB?
Currently, no hedge funds are holding shares in SE:MODTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Modus Therapeutics Holding AB
Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. Its lead product is Sevuparin, a polysaccharide to treat patients with sepsis and septic shock, which is under Phase Ib clinical study. The company was founded in 2011 and is headquartered in Stockholm, Sweden.
Technical Analysis
Isofol Medical AB
―
Xintela AB
―
Elicera Therapeutics AB
―
Active Biotech AB
―
NextCell Pharma AB
―